Skip to main content
. 2016 Mar 31;184(3):338–346. doi: 10.1111/cei.12767

Figure 1.

Figure 1

Complement activation and regulation in multi‐bacillary leprosy patients with and without reactions from Bangladesh. Meso Scale discovery (MSD) platform for measuring complement activation products C4d (a), mid‐borderline (Bb) (b), inactive complement component 3b (iC3b) (c), terminal complement complex (TCC) (d) and clusterin (e) in serum from endemic controls (n = 20) and multi‐bacillary leprosy patients with (n = 12) or without (n = 46) reaction at intake, showing a significant increase in multi‐bacillary leprosy patients with and without reaction compared controls for all measured components (P < 0·05). Complement component 4 deposition (C4d) levels are increased specifically and significantly in patients with reaction compared to those without reaction (b) [mean C4d no reaction 8·83 mg/l, standard error (s.e.) = 0·77] versus mean C4d reaction 13·41 mg/l (s.e. = 1·60); P < 0·05]. In addition, clusterin levels were increased significantly in serum of multi‐bacillary leprosy patients compared to endemic controls, but no difference between patients with or without reactions (e) [mean clusterin no reaction 398·0 mg/l (s.e. = 10·15); P < 0·001 versus mean clusterin reaction 378·9 mg/l (s.e. = 15·87); P < 0·05]. The error bars represent the standard error of the mean (s.e.).